See more : CviLux Corporation (8103.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Purple Biotech Ltd. (PPBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Purple Biotech Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nagreeka Exports Limited (NAGREEKEXP.BO) Income Statement Analysis – Financial Results
- Trainline Plc (TRN.L) Income Statement Analysis – Financial Results
- Fuse Group Holding Inc. (FUST) Income Statement Analysis – Financial Results
- Pioneer Merger Corp. (PACXW) Income Statement Analysis – Financial Results
- Godolphin Resources Limited (GDPHF) Income Statement Analysis – Financial Results
Purple Biotech Ltd. (PPBT)
About Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | -910.00K | -320.00K | 1.00M | 1.00M | 1.00M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 196.00K | 201.00K | 231.00K | 235.00K | 80.00 | 0.00 | 4.00K | 2.00K | 999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -196.00K | -1.11M | -551.00K | 765.00K | 999.92K | 1.00M | 897.00K | -2.00K | -999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 122.09% | 172.19% | 76.50% | 99.99% | 100.00% | 99.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.03M | 16.32M | 11.83M | 7.49M | 2.67M | 5.27M | 4.64M | 4.18M | 2.56M | 3.19M | 109.00K | 94.00 |
| General & Administrative | 0.00 | 5.96M | 5.82M | 6.07M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Selling & Marketing | 0.00 | 321.00K | 286.00K | 235.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.04M | 6.28M | 6.11M | 6.31M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Other Expenses | -44.54M | 0.00 | 0.00 | -15.66M | -216.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -22.47M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Cost & Expenses | -22.27M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Interest Income | 474.00K | 969.00K | 320.00K | 254.00K | 151.00K | 93.00K | 106.00K | 138.00K | 94.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.18M | 126.00K | 212.00K | 61.00K | 181.00K | 576.00K | 26.00K | 6.00K | 3.00K | 21.00K | 48.00K | 0.00 |
| Depreciation & Amortization | 199.00K | 201.00K | 231.00K | 235.00K | 178.00K | 7.00K | 4.00K | 2.00K | 1.00K | -50.00K | -27.00K | 957.22 |
| EBITDA | -22.23M | -21.49M | -17.52M | -28.41M | -6.14M | -5.55M | -12.88M | -7.04M | -4.20M | -5.43M | -2.58M | 255.22 |
| EBITDA Ratio | 0.00% | 2,355.27% | 5,432.19% | -2,796.00% | -763.80% | -772.60% | -1,323.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 22.27M | -22.60M | -17.93M | 12.61M | -7.16M | -7.83M | -12.25M | -7.18M | -4.07M | -5.18M | -2.55M | -702.00 |
| Operating Income Ratio | 0.00% | 2,483.85% | 5,604.38% | 1,261.20% | -715.60% | -782.60% | -1,359.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -42.25M | -43.52M | 108.00K | -15.46M | 1.48M | 2.26M | -947.00K | -4.94M | -133.00K | -71.00K | -75.00K | -1.00 |
| Income Before Tax | -19.98M | -21.76M | -17.83M | -28.07M | -5.89M | -5.57M | -13.01M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Income Before Tax Ratio | 0.00% | 2,391.21% | 5,570.63% | -2,807.40% | -589.30% | -556.90% | -1,443.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -935.00K | 637.00K | -15.67M | 216.00K | -2.63M | 26.00K | 4.94M | 133.00K | 50.00K | 27.00K | 0.00 |
| Net Income | -19.88M | -20.83M | -18.46M | -12.41M | -6.11M | -5.20M | -12.27M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Net Income Ratio | 0.00% | 2,288.46% | 5,769.69% | -1,240.50% | -610.90% | -520.00% | -1,362.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.49 |
| EPS Diluted | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.41 |
| Weighted Avg Shares Out | 221.33M | 18.48M | 17.80M | 17.21M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.00 |
| Weighted Avg Shares Out (Dil) | 221.33M | 18.48M | 17.80M | 17.21M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.55 |
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment...
Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
Preliminary Data from First Part of Study Anticipated in Second Half of 2021
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that...
Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers
Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb
Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that...
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Robert Gagnon to...
PPBT Stock: 9 Things for Investors to Know About Purple Biotech as Shares Surge
Purple Biotech (PPBT) stock is heading higher on Wednesday with heavy trading of the shares despite a lack of news about the company. The post PPBT Stock: 9 Things for Investors to Know About Purple Biotech as Shares Surge appeared...
Purple Biotech to Present at the B. Riley Oncology Investor Conference
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple Biotech management team will present a...
Source: https://incomestatements.info
Category: Stock Reports